Structure Therapeutics (NASDAQ:GPCR) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a strong sell rating in a report published on Sunday.

Several other equities analysts have also commented on GPCR. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research note on Friday. HC Wainwright reduced their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Finally, Citizens Jmp decreased their target price on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a research note on Friday, August 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Price Performance

Shares of GPCR opened at $52.13 on Friday. The stock’s 50-day moving average is $48.24 and its two-hundred day moving average is $53.39. The stock has a market cap of $3.70 billion, a PE ratio of -52.13 and a beta of -1.43. Structure Therapeutics has a 12 month low of $17.52 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, research analysts anticipate that Structure Therapeutics will post -1.78 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds have recently bought and sold shares of GPCR. Wellington Management Group LLP raised its position in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after buying an additional 1,150,000 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Structure Therapeutics by 5.2% during the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after buying an additional 264,833 shares in the last quarter. BVF Inc. IL increased its stake in shares of Structure Therapeutics by 8.6% in the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock worth $241,966,000 after buying an additional 275,105 shares during the last quarter. Finally, Morgan Stanley increased its stake in shares of Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.